Loading organizations...
§ Private Profile · Berlin, Germany
Myos is a technology company.
MYOS Corp develops advanced nutritional products featuring Fortetropin, a proprietary ingredient derived from raw fertilized egg yolk. This ingredient is scientifically formulated to maximize muscle health by reducing myostatin, promoting lean muscle mass, improving mobility, and mitigating atrophy in humans and animals. The company substantiates its product efficacy through clinical research and holds numerous patents.
Founded in the early 2010s by Robert J. Hariri, a distinguished surgeon, biomedical scientist, and entrepreneur, MYOS originated from the insight that muscle health's crucial role in overall well-being was often overlooked. Hariri and his team identified Fortetropin as a natural solution to address this significant physiological need, leading to the company's establishment around this discovery.
MYOS products serve diverse clientele, including aging populations, individuals undergoing rehabilitation, and pets recovering from surgery. The company's mission is to enhance quality of life and longevity by fostering strong, healthy muscles. MYOS aims for continued leadership in muscle health research, striving to deliver scientifically validated solutions that empower both people and animals to live healthier, more active lives.
Myos has raised $49.1M across 4 funding rounds.
Myos has raised $49.1M in total across 4 funding rounds.
Myos has raised $49.1M across 4 funding rounds. Most recently, it raised $30.0M Series A in June 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 22, 2021 | $30M Series A | Fasanara Capital, Eugene Timko | Tomahawk VC | Announced |
| Mar 1, 2021 | $6M Series A | — | Xploration Capital | Announced |
| Oct 1, 2020 | $2M Seed | — | Antler, Lakestar, Omnis Mundi, Picus Capital, Felix Jahn, Hakan KOC, Heiko Rauch, Lukas Brosseder, Oliver Roskopf, Robert Maier | Announced |
| Oct 24, 2019 | $11.1M Venture Round | — | Gerald Schönbucher, Avala Capital, Berlin Technologie Holding, Mountain Partners | Announced |
MYOS Corp (formerly MYOS RENS Technology Inc.) is a Cedar Knolls, New Jersey-based biotechnology and advanced nutrition company founded in 2011, specializing in muscle health solutions through its proprietary ingredient Fortetropin, derived from fertilized egg yolk.[1][2][3] Fortetropin is clinically shown to build muscle, improve mobility, reduce atrophy, and aid recovery from injury or aging in both humans and animals, targeting healthcare, human nutrition, and animal health sectors with products like MYOS Canine Muscle Formula and Qurr.[2][3][4] The company has raised $250K, gone public via IPO, holds 9 patents (with 19 filed), and supports its claims with 8 clinical studies, serving over 3,000 veterinary hospitals while expanding direct-to-consumer and clinic sales.[1][2][4]
Despite early revenue challenges and earnings losses noted around 2019, MYOS has pivoted successfully to animal health, demonstrating growth through veterinary partnerships and positive clinical outcomes like improved LOAD scores in mobility tests for dogs.[4][5]
MYOS was founded in 2011 by a team of scientists and physicians who identified a critical gap in medicine: insufficient focus on muscle health despite its role in overall well-being, recovery from conditions like sarcopenia, cachexia, and injury.[2][4] Motivated by this, they invested in research with a food technology company to develop Fortetropin, a bioavailable fertilized egg yolk formulation that preserves natural muscle-building compounds.[4]
Initial traction came from the bodybuilding community, but a pivotal moment occurred when customers reported dramatic mobility improvements in their aging and injured dogs after using Fortetropin, prompting formal veterinary trials that confirmed results within 1-2 months.[4] This led to the launch of the animal health division, rapid expansion to veterinary clinics, and a 2020 corporate restructuring where MYOS RENS Technology merged assets into MYOS Corp as a private entity focused on human and animal nutrition.[3][4]
MYOS rides the wave of personalized nutrition and biotech advancements in muscle health, addressing rising demands from aging populations, sports performance, and pet wellness amid increasing sarcopenia and mobility issues in humans and animals.[1][2][4] Timing aligns with post-2020 growth in animal health tech, fueled by pet humanization trends and veterinary rehab needs, where Fortetropin's natural, evidence-based alternative to pharmaceuticals fills a market gap in non-invasive recovery solutions.[3][4]
Market forces like CDC-reported rises in age-related diseases and pet ownership booms favor its expansion, influencing the ecosystem by setting standards for clinically validated nutraceuticals and inspiring similar biotech innovations in preventive health.[1][4] As a bridge between food tech and biotech, MYOS contributes to broader shifts toward muscle-centric wellness in healthcare and veterinary fields.[2][6]
MYOS is poised for sustained growth in animal health, leveraging its veterinary network and clinical data to capture more market share in mobility and recovery products, while human nutrition applications could expand via partnerships amid rising wellness trends.[2][3][4] Emerging trends like AI-driven personalized nutrition, longevity biotech, and premium pet care will shape its path, potentially amplifying Fortetropin's role through new formulations or global scaling.[1][2]
Its influence may evolve from niche innovator to muscle health leader, especially if ongoing R&D yields breakthroughs in areas like spray-dried follistatin (patent granted 2025), tying back to its foundational mission of redefining health through overlooked natural muscle solutions.[1][4]
Myos has raised $49.1M in total across 4 funding rounds.
Myos's investors include Fasanara Capital, Eugene Timko, Tomahawk VC, Xploration Capital, Antler, Lakestar, Omnis Mundi, Picus Capital, Felix Jahn, Hakan Koc, Heiko Rauch, Lukas Brosseder.